|

Middle East Study of Infections in Patients With Hematological Malignancies

RECRUITINGSponsored by Hamad Medical Corporation
Actively Recruiting
SponsorHamad Medical Corporation
Started2024-09-15
Est. completion2028-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT) recipients across the Middle East. The objectives are to describe the epidemiological trends, identify risk factors for inappropriate antimicrobial therapy, and predictors of persistent BSI, microbiological relapse, and all-cause mortality. The study is entirely observational, participants will receive standard clinical care as directed by their treating doctors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Active underlying hematological malignancy or hematopoietic stem cell transplant recipient.
* Bloodstream infection ( a blood culture yielding a growth of ≥1 micro-organism that is considered to be clinically significant and is actively treated by the attending physicians).

Exclusion Criteria:

* A bloodstream infection within 14 days of an already enrolled bloodstream infection, or at any time before resolution of active signs of infections associated with an already enrolled episode.

Conditions4

Bloodstream InfectionCancerHematological MalignancyHematopoetic Stem Cell Transplantation

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.